Latest MediciNova News & Updates
See the latest news and media coverage for MediciNova. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing novel therapeutics
medicinova.com- Headquarters
- La Jolla, United States
- Company type
- Public company
- Number of employees
- 15–50
Last updated
Latest news about MediciNova
In short: MediciNova advanced its lead candidate MN-166 through clinical trials for ALS and MS while securing new funding and regulatory advisory expertise.
Company announcements
-
MediciNova announces ibudilast study in Cancer Research
The peer-reviewed study highlights ibudilast inhibiting MIF-mediated reprogramming in brain metastasis models, identifying MIF as a biomarker.
-
MediciNova collaborates with Mayo Clinic on ALS program
The SEANOBI EAP evaluates MN-166 (ibudilast) for ALS patients, generating real-world data complementing the COMBAT-ALS study.
-
MediciNova announces peer-reviewed study on ibudilast for brain metastasis
The study identifies MIF-CD74 signaling as a target, showing ibudilast suppresses metastasis in preclinical models. MediciNova plans clinical collaboration with CNIO.
-
MediciNova advances MN-166 trial for ALS
The Phase 2B/3 study evaluates slowing progression, improving outcomes, and extending survival in ALS patients.
Media coverage
-
Ibudilast Slows Retinal Thinning in Progressive MS | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
New analyses from the phase 2b SPRINT-MS trial suggest that MediciNovas ibudilast (also known as MN-166), can lessen retinal thinning as measured by optical coherence...
-
Analysts Set MediciNova, Inc. (NASDAQ:MNOV) Price Target at $8.00 - Markets Daily
MediciNova, Inc. (NASDAQ:MNOV – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company...
-
MediciNova’s (MNOV) “Buy” Rating Reiterated at Maxim Group - Daily Political
Maxim Group reiterated their buy rating on shares of MediciNova (NASDAQ:MNOV – Free Report) in a research report released on Monday, MarketBeat.com reports. The firm...
-
HC Wainwright & Co. initiates coverage of MediciNova (MNOV) with buy recommendation
Fintel reports that on March 16, 2026, HC Wainwright & Co. initiated coverage of MediciNova (NasdaqGM:MNOV) with a Buy recommendation. Analyst Price Forecast Suggests 603.40...
Track MediciNova and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
MediciNova competitors & trending companies
Browse news for competitors to MediciNova and other trending companies.
Clene
Raya
Prilenia Therapeutics
Origami Therapeutics
Tiziana Life Sciences
Asarina Pharma
AlzeCure Pharma
Alzinova
Mitochon Pharmaceuticals
Agomab Therapeutics
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax